Terms: = Skin cancer AND TRIM24, O15164, 8805, ENSG00000122779, TIF1ALPHA, TF1A, TIF1A, hTIF1, Tif1a, TIF1, RNF82, PTC6 AND Treatment
12 results:
1. Paraneoplastic anti-tif1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract] [Full Text] [Related]
2. Clinical features of dermatomyositis patients with anti-tif1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract] [Full Text] [Related]
3. A Case in Which Breast cancer Developed at the Same Time As Dermatomyositis, and the Onset of New cancer Was Able to Be Predicted by the Exacerbating skin Symptoms and Parallel Increase in the Anti-tif1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract] [Full Text] [Related]
5. Anti-Mi-2 and Anti-tif1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract] [Full Text] [Related]
6. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract] [Full Text] [Related]
7. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract] [Full Text] [Related]
8. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract] [Full Text] [Related]
9. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract] [Full Text] [Related]
10. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.
Gono T; Kuwana M
Expert Rev Clin Immunol; 2020 Jan; 16(1):79-89. PubMed ID: 31779485
[No Abstract] [Full Text] [Related]
11. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract] [Full Text] [Related]
12. Melanoma and IFN alpha: potential adjuvant therapy.
Bottoni U; Clerico R; Paolino G; Corsetti P; Ambrifi M; Brachini A; Richetta A; Nisticò S; Pranteda G; Calvieri S
J Biol Regul Homeost Agents; 2014; 28(2):271-9. PubMed ID: 25001659
[TBL] [Abstract] [Full Text] [Related]
